{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-022772","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2025-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.721742+00:00","generated_at":"2026-05-18T06:24:36.786315+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Henry Ford Health enrolls first patients in BioCardia's Phase 3 CardiAMP HF II trial","bullets":["Henry Ford Health (Detroit) is now enrolling ischemic HFrEF patients in BioCardia's pivotal CardiAMP HF II trial.","CardiAMP HF II is a 250-patient randomized, placebo-controlled confirmatory study of autologous bone marrow cell therapy.","Primary composite endpoint includes all-cause death, nonfatal MACE, and quality of life; prior CardiAMP HF trial met significance for elevated NTproBNP patients.","Therapy involves same-day cell harvest, bedside processing, and minimally invasive catheter delivery."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-022772","json":"https://secwatch.observer/filing/0001437749-25-022772.json","markdown":"https://secwatch.observer/filing/0001437749-25-022772.md","text":"https://secwatch.observer/filing/0001437749-25-022772.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774925022772/0001437749-25-022772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774925022772/bcda20250716_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:24:36.786315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}